


Prof. Dr. med. Björn Chapuy

Name	Prof. Dr. med. Björn Chapuy
Date of birth	June 12, 1977
Gender/Family	male, married, two daughters (6 & 6)
Work address	University of Göttingen University Medical Center (UMG) Department of Hematology and Oncology Robert-Koch Str. 40 37075 Göttingen, Germany
Phone	+ 49 (0)551 39-7075
E-mail	bjoern.chapuy@med.uni-goettingen.de
Current position	Professor for Tumor Biology and Signal Transduction (W2tt), UMG



Academic education

Since 2021	Attending, Dept. Hematology and Medical Oncology, UMG
2020	Board certification Internal Medicine, Hematology and Medical Oncology
2018 - 2020	Senior physician in the Department of Hematology and Oncology, Department of Hematology and Oncology, UMG, Germany
2001-2006	M.D. thesis, Dept. Biochemistry/Cell biology, UMG, Germany
2004 - 2008	Combined residency and clinical fellowship in Hematology and Oncology, Department of Hematology and Oncology, UMG, Germany
1997-2004	Medical School, UMG, Germany

Scientific degrees

Since 2018	Associate Professor, Lymphoma Biology and Signal Transduction, UMG, Germany
2012	Instructor in Medicine (Junior Faculty), Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
2006	Dr. med.; UMG, Germany
2004	Final Medical Examination, UMG, Germany

Scientific career

Since 2018	Professor of Lymphoma Biology and Signal Transduction (W2 tenure track), UMG, Germany
2012 - 2018	Instructor in Medicine (Junior Faculty), Lymphoma Program am Dana-Farber Cancer Institute und Harvard Medical School, Boston, MA, USA
Since 2009	Affiliated Member, Broad Institute, Cambridge, MA, USA
2008 - 2012	Postdoctoral fellow with Prof. Dr. M. Shipp, Lymphoma Program, Dana-Farber Cancer Institute/Harvard Medical School (DFCI/HWS), Boston, MA, USA
2004 - 2008	Research associate with Prof. Dr. G. Wulf, Department of Hematology and Oncology, UMG, Germany

Additional Information

Since 2018	Coordination team, Else Kröner-Fresenius MD Program (Promotionskolleg), UMG
2018	Gilead Science Oncology Award winner
Since 2014	Ad hoc reviewer for <i>Cancer Discovery</i> , <i>Nature Communication</i> , <i>Blood</i> , <i>Leukemia</i> , <i>Embo J</i> , <i>Cancer Research</i> , <i>Blood Advances</i> , <i>Clinical Cancer Research</i> , <i>Hematologica</i> , etc.
2016	Medical Oncology Translational Grant Award, DFCI/HWS
2014	Claudia Adams Barr Award for Basic Cancer Research, , DFCI/HWS
2012-2015	American Society of Hematology Achievement Award (each year)
2008-2010	Research Fellowship, DFG
2006	Junior Research Fellowship, UMG
2006	M.D thesis " <i>summa cum laude</i> "

10 most relevant publications out of 62 (h-index 40 | 10,871 citations):

1. Aung T*, **Chapuy B*** (*=equal contributions), Vogel D, Wenzel D, Oppermann M, Lahmann M, Weinlage T, Menck K, Hupfeld T, Koch R, Truemper L, Wulf GG. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. *Proc Natl Acad Sci U S A*. 2011 Sep 13;108(37):15336-41.
2. Duan S*, Cermak L* , (*=equal contributions), Pagan J, Rossi M, Francia di Celle P, **Chapuy B**, Shipp B, Chiarle R, Pagano M: The F-box protein FBXO11 targets BCL6 for degradation and is mutated in Diffuse Large B-Cell Lymphomas, leading to BCL6 stabilization. *Nature*. 2012 Jan 5;481(7379):90-3.
3. Monti S*, **Chapuy B*** (*=equal contributions), Takeyama K, Rodig SJ, Hao Y, Yeda KT, Inguilizian H, Mermel C, Curie T, Dogan A, Kutok JL, Beroukim R, Neuberg D, Habermann T, Getz G, Kung AL, Golub TR, Shipp MA: Integrative Analysis Reveals an Outcome-associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B-cell Lymphoma. *Cancer Cell*. 2012 Sep 11;22(3):359-72.
4. **Chapuy B***, McKeown MR* (*=equal contributions), Lin CY, Monti S, Roemer MG, Qi J, Rahl PB, Sun H, Yeda KT, Doench JG, Reichert E, Kung AL, Rodig SJ, Young RA, Shipp MA, Bradner JE: Discovery and Characterization of Super-Enhancer Associated Dependencies in Diffuse Large B-Cell Lymphoma. *Cancer Cell*. 2013 Dec 9;24(6):777-90.
5. Lane AA, **Chapuy B**, Lin CY, Tivey T, Li H, Townsend EC, van Bodegom D, Day TA, Wu S, Liu H, Yoda A, Alexe G, Schinze AC, Sullivan TJ, Malinge S, Taylor JE, Stegmaier K, Jaffe JD, Bustin M, te Kronnie G, Izraeli S, Harris M, Stevenson KE, Neuberg D, Silverman LB, Sallan SE, Bradner JE, Hahn WC, Crispino JD, Pellman D, Weinstock DM: Chr.21q22 triplication contributes to B cell transformation through HMGN1 and loss of H3K27me3. *Nat Genet*. 2014 Jun;46(6):618-23.
6. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattray D, Freeman GJ, Rodig SJ, **Chapuy B**, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. *N Engl J Med*. 2015 Jan 22;372(4):311-9.
7. Karreth FA, Reschke M, Ruocco A, Ng C, **Chapuy B**, Léopold V, Sjöberg M, Keane TM, Verma A, Ala U, Tay Y, Seitzer N, Bothmer A, Fung J, Langellotto F, Rodig SJ, Elemento O, Shipp MA, Adams DJ, Chiarle R, Pandolfi PP: The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo. *Cell*. 2015 Apr 9;161(2):319-32.
8. **Chapuy B***, Roemer MGM* (*=equal contributions), Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, Linden E, Sun HH, Homer H, Aono M, Pinkus GS, Ligon AH, Ligon K, Ferry JA, Freeman G, van Hummelen P, Golub TR, Getz G, Rodig SJ, de Jong D, Monti S, Shipp MA: Targetable Genetic Features of Primary Testicular and Primary Central Nervous System Lymphomas. *Blood*. 2016 Feb 18;127(7):869-81.
9. **Chapuy B***, Cheng H* (*=equal contributions), Watahiki A, Ducar MD, Tan Y, Chen L, Roemer MGM, Ouyang J, Christie AL, Zhang L, Gusenleitner D, Abo RP, Farinha P, von Bonin F, Thorner AR, Sun HH, Gascoyne RD, Pinkus GS, van Hummelen P, Wulf GG, Aster JC, Weinstock DM, Monti S, Rodig SJ, Wang Y, Shipp MA. Diffuse Large B-cell Lymphoma Patient-derived Xenograft Models Capture the Molecular and Biologic Heterogeneity of the Disease. *Blood*. 2016 May 5;127(18):2203-13.
10. **Chapuy B***, Stewart C*, Dunford A* (* denotes equal contribution), Kim J, Kamburov A, Redd R, Lawrence M, Roemer MGM, Li AJ, Ziepert M, Wala J, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin C, Hess J, Pedamallu C, Livitz D, Rosenbrock D, Rosenberg M, Tracy A, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson M, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg D, Loeffler M, Pfreundschuh M, Trümper L, Getz G*, Shipp MA*. Molecular Subtypes of Diffuse Large B-cell Lymphoma are Associated with Distinct Pathogenic Mechanisms and Outcomes. *Nat Med* 2018; 24(5):679-690.